Global Lung Cancer Diagnostics Market - 2023-2030

Global Lung Cancer Diagnostics Market - 2023-2030

Global lung cancer diagnostics market reached US$ xx billion in 2022 and is expected to reach US$ xx billion by 2030, growing with a CAGR of xx% during the forecast period 2023-2030.

The global lung cancer diagnostics market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Lung cancer usually affects smokers and has its origins there. The third most frequent cancer in the United States is lung cancer. It results from the unregulated growth of dangerous cells in the lungs.

NSCLC report around 80–85% of lung cancer cases. Imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) scans are used to identify lung cancer.

Government investments and research, particularly in developing economies, will continue to drive utilization of advanced technology for novel diagnosis such as biomarker testing or next generation sequencing assay for small or non-small cell lung cancer and boost the global lung cancer diagnostics market.

Market Dynamics: Drivers & Restraints

Initiation of several collaborations or partnerships

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for lung cancer diagnostics owing to the rising cases of lung cancer. Various collaborations, acquisitions and license agreement with technological advancements among different countries will be a crucial factor driving the growth of the market.

On May 9, 2023, increasing local availability of next-gen sequencing (NGS)-based evaluation for breast and lung cancer patients in over thirty nations across Latin America, Africa, the Middle East, and Asia where developed genomic testing was previously restricted or unavailable is the goal of a collaboration agreement between Pfizer and Thermo Fisher Scientific Inc.

Additionally, on June 23, 2023, the Rajiv Gandhi Cancer Institute or Research Center (RGCI&RC) and AstraZeneca Pharma India Ltd. inked a Memorandum of Understanding (MOU), a science-driven biopharmaceutical enterprise. Through this partnership, a Center of Excellence (CoE) will be established at the RGCI&RC facility in Delhi to increase the accessibility of Next-Generation Sequencing (NGS) molecular panel testing that is verified, high-quality, and subsidised for eligible Indian patients with lung cancer.

Furthermore, the rising utilization of novel medicines and solutions for lung cancer. Rising non small cell lung cancer cases and increasing utilization of several novel diagnostic kits or assay along with research for innovative product development will be a major factor driving the growth of the lung cancer diagnostics market.

Limitations associated with lung cancer diagnosis

Tumor heterogeneity presents a diagnostic difficulty for lung cancer, making molecular analysis crucial. 1255 lung cancers were examined by the Clinical Lung Cancer Genome Project and Network genetic Medicine, and it was discovered that 55% of them exhibited at least one genetic change that may be susceptible to targeted therapy. Given the significance of genomic testing prior to beginning treatment for patients with advanced lung cancer, the number of diagnostic platforms accessible for lung cancer genomic profiling has risen in recent years.

The expense of molecular testing, its quality and standards, its accessibility within an institution, knowledge of the most latest guidelines, the length of time required for results, and inconsistent findings are all obstacles to the broad acceptance of molecular testing worldwide.

Segment Analysis

The global lung cancer diagnostics market is segmented based on type, diagnosis, end user and region.

Non-small cell lung cancer type segment accounted for approximately 83% of market share

Any epithelial lung cancer (ESCC) besides small cell lung cancer (SCLC) is referred to as NSCLC. Large cell carcinoma, squamous cell carcinoma, and adenocarcinoma are the three most prevalent kinds of NSCLC; however, there are a number of additional types that are less common and all types can manifest in odd histological variants.

Adenocarcinomas can be identified in patients who have never smoked, despite the fact that NSCLCs are linked to cigarette smoke. Confirming the diagnosis and figuring out the severity of the illness are the main goals of investigations into patients with suspected NSCLC. The histology, stage, and overall well-being and comorbidities of the individual in question all influence the treatment options.

On March 6, 2023, according to Roche, the FDA has granted approval for the VENTANA PD-L1 (SP263) Assay for use as a companion diagnostic to help doctors determine which patients having non-small cell lung cancer (NSCLC) are candidates for treatment with the PD-1 inhibitor drug Libtayo (cemiplimab), which was created by Regeneron.

Furthermore, on March 27, 2023, for the 40 mg and 80 mg selpercatinib capsules, Amoy Diagnostics Co., Ltd., Riken Genesis Co., Ltd., and Precision Medicine Asia Co., Ltd. received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the AmoyDx Pan Lung Cancer PCR Panel to be a companion diagnostic for RET fusion-positive non-small cell lung cancer.

Geographical Penetration

North America accounted for around 39% of market share in 2022

Due to the rising need for lung cancer diagnostics in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for lung cancer diagnostics.

Increasing expenditure on healthcare, advancement of technologies and different types of diagnostics for lung cancers, along with increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of lung cancer diagnostics market share of this region. The market in this area is growing as people become more aware of various novel diagnostic products. The aforementioned elements attest to North America's hegemonic position in the world.

North America continues to be a key player in the global lung cancer diagnostics market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for biomarker assays or imaging tests in the United States have been proactive in executing several initiatives or surgical procedures, stimulating these diagnostic products demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global lung cancer diagnostics market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of assays or kits, was significantly impacted. The widespread lockdowns and restrictions imposed by the pandemic, which began in early 2020, had an effect on a number of initiatives all around the world.

Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for lung cancer diagnostics. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global lung cancer diagnostics market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for diagnostic products.

By Type
• Small Cell Lung Cancer
Small Cell Carcinoma
Combined Small Cell Carcinoma
• Non-small Cell Lung Cancer
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Others

By Diagnosis
• Imaging Tests
• Sputum Cytology
• Biopsy
• Biomarker Testing
• Others

By End User
• Hospitals
• Diagnostic Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On August 24, 2023, Agilent Technologies Inc. revealed that PD-L1 IHC 22C3 pharmDx, Code SK006 received a companion diagnostic (CDx) Class C IVDR certification. This CDx test has been certified in line with the recently introduced EU standards for in vitro diagnostic medical devices (IVDR), which was previously CE-IVD-marked for sales in the European Union.
• On July 27, 2023, GEnome-wide Mutational Incidence for Non Invasive (GEMINI ) Detection of Cancer, is a novel, highly precise technique for identifying somatic genomic alterations in cell-free DNA (cfDNA). It was developed by DELFI Diagnostics, a pioneer in the development of a new class of high-performance, affordable liquid biopsy tests for early cancer detection and monitoring. Researchers have successfully detected tumor-specific mutations across the entire genome for the first time using the same low-coverage genome-wide sequencing techniques that serve as the foundation of the DELFI Diagnostics platform.
• On January 18, 2022, the novel GeneStrat NGS genomic examination, a blood-based cancer profiling test, was introduced by Biodesix, Inc., a prominent provider of data-driven diagnostic solutions with a focus on lung illness. In order to discover targeted therapy mutations, including EGFR, KRAS, ALK, MET, ERBB2, NTRK, and others, and to deliver them in a timely manner, the 52-gene panel comprises mutations that are indicated by guidelines for treating patients with advanced-stage lung cancer.

Competitive Landscape

The major global players in the market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Quest Diagnostics Incorporated, DELFI Diagnostics, Agilent Technologies Inc., Amoy Diagnostics Co., Ltd., Siemens Healthcare Private Limited, Biodesix and QIAGEN.

Why Purchase the Report?
• To visualize the global lung cancer diagnostics market segmentation based on type, diagnosis, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of lung cancer diagnostics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global lung cancer diagnostics market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies